髂动脉分支装置保留髂内动脉在肾下腹主动脉髂动脉瘤腔内修复中的长期耐久性
本研究基于前瞻性医生发起IDE试验,比较肾下腹主动脉髂动脉瘤患者接受标准EVAR与EVAR联合髂动脉分支装置(IBD)保留顺行髂内动脉灌注的长期结局。75例EVAR-IBD与255例标准EVAR随访10年,IBD技术成功率97%,30天死亡率1.3%,3/5/10年动脉瘤相关死亡免除率99%,IBD一期通畅率3/5/10年分别为94%/94%/77%。EVAR-IBD组二次再干预显著少于合并AIA行标准EVAR组(HR 0.476,95%CI 0.226-1.001;P=.045)。
要点
- IBD保留髂内动脉顺行血流技术成功率97%,30天死亡率1.3%。
- 10年动脉瘤相关死亡免除率99%,IBD一期通畅率10年77%。
- EVAR-IBD组二次再干预显著少于合并AIA标准EVAR组。
核心结论
- 使用IBD保留髂内动脉顺行血流的EVAR治疗肾下腹主动脉髂动脉瘤可行,且长期耐久性持续。
- 对符合解剖标准的肾下腹主动脉髂动脉瘤患者,应认真考虑使用IBD。
研究设计与样本
- 前瞻性医生发起的研究性器械豁免(IDE)试验,1998年10月至2015年8月入组常规开放手术高风险的肾下腹主动脉髂动脉瘤患者。
- 分析75例EVAR-IBD患者与255例标准EVAR患者的临床数据,随访10年。
- 评估技术成功、围手术期结局、死亡率、器械通畅率、内漏率及再干预。
主要发现
- 75例患者共置入87个IBD,技术成功率97%,30天死亡率1.3%。
- 3、5、10年动脉瘤相关死亡免除率均为99%。
- 3、5、10年I型或III型内漏免除率均为99%。
- 3、5、10年二次再干预免除率分别为86%、81%、81%。
- IBD一期通畅率3、5、10年分别为94%、94%、77%。
关键数值与推荐
- EVAR-AIA与EVAR-IBD在动脉瘤相关死亡免除率、肢体闭塞或内漏率上无统计学显著差异(P > .05)。
- EVAR-AIA组二次再干预显著多于EVAR-IBD组(风险比0.476,95%CI 0.226-1.001;P = .045)。
临床怎么用
- 对于常规开放手术高风险的肾下腹主动脉髂动脉瘤患者,EVAR-IBD可保留髂内动脉顺行灌注并维持长期耐久性。
- 符合解剖标准的患者应认真考虑使用IBD,以减少二次再干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study evaluated and compared the long-term clinical outcomes of endovascular repair of infrarenal aortoiliac aneurysms (EVAR) vs EVAR with preservation of antegrade internal iliac artery (IIA) perfusion using iliac branched devices (EVAR-IBDs). METHODS: From October 1998 to August 2015, patients with infrarenal aortoiliac aneurysmal (AIA) disease at high risk for conventional open surgery were enrolled in a prospective physician-sponsored investigational device exemption trial. Clinical data of 75 patients treated with EVAR-IBD and 255 with standard EVAR were analyzed. Technical success, perioperative outcomes, mortality, device patency, endoleak rates, and reinterventions during a follow-up of 10 years were analyzed. RESULTS: There were 87 IBDs deployed in 75 patients. Technical success rate was 97%. Mortality at 30 days was 1.3%. Freedom from aneurysm-related mortality at 3, 5, and 10 years was 99%. Freedom from a type I or III endoleak at 3, 5, and 10 years was 99%. Freedom from secondary reinterventions at 3, 5, and 10 years was 86%, 81%, and 81%, respectively. Primary patency of the IBDs at 3, 5, and 10 years was 94%, 94%, and 77%, respectively. Twenty-four percent of patients underwent EVAR for concomitant AIA disease (EVAR-AIA), and 78% were managed by staged IIA embolization before EVAR. No statistically significant difference in freedom from aneurysm-related mortality, limb occlusions, or endoleak rates was identified in patients with EVAR-AIA vs EVAR-IBD (P > .05). There were significantly more secondary reinterventions in the EVAR-AIA group compared with the EVAR-IBD group (hazard ratio, 0.476, 95% confidence interval, 0.226-1.001; P = .045). CONCLUSIONS: EVAR of infrarenal AIAs with preservation of antegrade flow to the IIA using IBDs is feasible with long-term sustained durability. Serious considerations should be given to the use of IBDs in patients with infrarenal AIAs meeting appropriate anatomic criteria.
引用
- Farivar BS, Abbasi MN, Dias AP, et al. Durability of iliac artery preservation associated with endovascular repair of infrarenal aortoiliac aneurysms. J Vasc Surg. 2017. PMID: 28502545. doi:10.1016/j.jvs.2017.02.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。